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Small molecules, big effects: the role of microRNAs
in regulation of cardiomyocyte death
J Skommer1,3, I Rana1,3, FZ Marques1, W Zhu2, Z Du2 and FJ Charchar*,1
MicroRNAs (miRNAs) are a class of small non-coding RNAs involved in posttranscriptional regulation of gene expression, and
exerting regulatory roles in plethora of biological processes. In recent years, miRNAs have received increased attention for their
crucial role in health and disease, including in cardiovascular disease. This review summarizes the role of miRNAs in regulation
of cardiac cell death/cell survival pathways, including apoptosis, autophagy and necrosis. It is envisaged that these miRNAs may
explain the mechanisms behind the pathogenesis of many cardiac diseases, and, most importantly, may provide new avenues
for therapeutic intervention that will limit cardiomyocyte cell death before it irreversibly affects cardiac function. Through an in-
depth literature analysis coupled with integrative bioinformatics (pathway and synergy analysis), we dissect here the landscape
of complex relationships between the apoptosis-regulating miRNAs in the context of cardiomyocyte cell death (including
regulation of autophagy–apoptosis cross talk), and examine the gaps in our current understanding that will guide future
investigations.
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Facts
 There are altered cardiac microRNAs levels in various
cardiovascular diseases states
 MicroRNAs can regulate cardiac cell proliferation, hyper-
trophy, death and cardiac fibrosis pathways.
 MicroRNAs have long biological half-lives, hence can be a
good diagnostic marker of disease state
Open Questions
 What are the mechanisms leading to increase or decrease
in cardiac microRNAs under pathological and physiological
state?
 What are the mechanisms by which microRNAs contribute
to cardiac pathological and physiological state?
 What are the cardiac microRNA changes associated with
aging?
 How do microRNAs regulate the balance between pro-
survival and death pathways in the heart?
Cell death processes are highly regulated in order to ensure
proper tissue functioning and homeostasis. Loss of cardio-
myocytes is an important factor in the pathogenesis of
conditions such as myocardial infarction (MI),1 and occurs
through a variety of cell death pathways, induction of which
depends not only on the type of stress stimuli, but also on the
intracellular biochemical and genetic makeup.2 Most impor-
tantly, the converging regulatory network of cell death
pathways is potentially amenable for control and therapeutic
intervention.3
Over the last several years, efforts have been directed
toward elucidating the exact regulatory mechanisms that
govern cell death processes, including protein oligomerisa-
tion, protein conformational changes, transient protein–
protein interactions and protein relocations (for example,
Vela et al.4–8), as well as non-genetic cell-to-cell variability.9–12
Recently, microRNAs (miRNAs) have emerged as an
important, perhaps critical, regulatory factor when it comes
to cell death signaling. This is not surprising considering that
miRNAs, a class of small non-coding RNAs, posttranscrip-
tionally regulate messenger RNAs by inhibiting their transla-
tion or promoting their degradation, and thus represent a new
paradigm that regulates the expression of up to 50% of human
genes.13,14 According to the latest version ofmiRNA database
miRBase 20.0, there are over 2500 known mature miRNAs in
the human genome.15
Increasing evidence indicates that miRNAs are linked with
many pathological conditions, and play important roles in
cardiovascular homeostasis and in initiation and progression
of disease states, such as hypertrophy and heart failure.16–18
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Considering the role of cell death processes in cardiovascular
disease (CVD) as well as the emerging role of miRNAs in
regulating cardiac physiological and pathological states, we
will focus our review on the role of miRNAs in regulating
myocardial cell death processes.
The World of miRNAs
Small non-coding RNA molecules of B22–23 nucleotides
in length, known as miRNAs, regulate the expression of
protein-coding genes through sequence-specific recognition
in the 30 or the 50 untranslated regions (UTRs) of mRNAs, thus
regulating mRNA levels by posttranscriptional mechan-
isms.14,19 Partial sequence complementarity between a
miRNA and its target site in a specific mRNA is often sufficient
for binding.20 In animals, the binding to the 30UTR lowers
mRNA levels by preferentially decreasing the stability of the
mRNA, thus increasing its degradation, or by repressing
translation.14 miRNAs were also described to bind to the
promoter region in the 50UTR of mRNAs.21,22 The binding of
miRNAs to 50UTRs can either repress or, most likely, activate
translation (reviewed by Da Sacco and Masotti19 and Vasude-
van23). Since no examples of this type of miRNA–mRNA
interactions are known in CVD or cell death, this review will
explore mechanisms involving miRNAs that bind to the 30UTR
of mRNAs only.
miRNA biogenesis has been extensively reviewed else-
where.24–26 Briefly, transcription of miRNA genes is usually
performed by RNA polymerase (RNAPol) II, or occasionally by
RNA Pol III, resulting in a precursor miRNA, termed primary
miRNA or pri-miRNA.26 In the nucleus pri-miRNAs (B1000bp)
fold into hairpin structures, which act as a substrate for DGCR8
subunit of Drosha, a nuclear enzyme of the RNase III family,
resulting in the cleavage of the pri-miRNA into a pre-miRNA
(B60—70-bp long). The pre-miRNA is then exported to the
cytoplasm, where Dicer, another enzyme of the RNAse III
family, processes the pre-miRNA to aB20-bp double-stranded
miRNA duplexes.24–26 The miRNA duplexes associate with
specific members of the Argonaute (Ago) family of proteins,
and together form the core of the RNA-silencing complex
(RISC), which mediates the posttranscriptional regulation of
gene expression by utilizing the guide strand (miR) of the
miRNA duplex.24–26 There is now evidence that the second
miRNA strand, often called passenger or minor miRNA (miR*),
before believed to be degraded, can also associate with Ago
proteins and impact gene expression.27
Several algorithms are used for the discovery of miRNA–
mRNA interactions (reviewed by Witkos et al.28), with
computational predictions suggesting that a single miRNA
can potentially regulate multiple mRNAs.20,28 In vitro experi-
mentation, however, is always necessary to validate the
predicted targets as well as the role of miRNAs in regulation of
cell signaling pathways and cellular phenotypes. Moreover,
the general role of miRNAs in specific cellular or physiological
processes can be examined by deleting or inhibiting miRNA-
processing machinery. For instance, the cardiac-specific
knockout of Dicer leads to rapidly progressive dilated
cardiomyopathy, heart failure and postnatal lethality, empha-
sizing the importance of miRNAs for heart development and
homeostasis.29–31
Types of Cell Death
Cell death is a group of fundamental processes in both normal
physiology and pathological states. The mammalian cell
death network comprises of many distinct functional mod-
ules,32–34 including apoptosis (also referred to as pro-
grammed cell death), macroautophagy (commonly referred
to as autophagy, and more appropriately as cell death
dependent on autophagy genes), necrosis and an inflamma-
tory form of cell death referred to as pyroptosis.35 Of these,
apoptosis has been studied most extensively and its
molecular framework is relatively well defined.36 Often more
than one process of cell death is induced, and the particular
extracellular milieu, as well as genetic and biochemical
context of the intracellular environment, will determine which
pathway is ultimately responsible for cell demise. Because of
this, blocking one pathway of cell death may not prevent the
final outcome of cell loss, as other simultaneously induced
pathways may take over the executioner’s role. At the same
time, genetic and pharmacological inhibitor studies can
identify the culprit pathway among all the signaling induced
by a particular stress cue. Thus, detailed knowledge of
multiple pathways, their regulators and cross talks between
them, is of paramount importance when it comes to interfering
with cell death process for therapeutic purposes.
Apoptotic Pathways in Cardiovascular Disease
The process of apoptosis is driven by a network of proteins
connected to each other in an intricate manner, forming two
main signaling pathways activated by a wide variety of stress
signals that converge on mitochondria (the intrinsic pathway)
or upon ligation of cell surface death receptors (the extrinsic
pathway) (Figure 1). Caspase-9 activation by mitochondrial
pathway and caspase-8 activation by extrinsic pathway lead
to activation of the executioner caspases, such as caspase-3
or -7 which then directly degrade the proteome and commit
cells to death (Figure 1).
Cytochrome c released from damaged mitochondria act as
a trigger for the activation of the mitochondrial pathway. The
mitochondrial pathway of apoptosis is heavily regulated by
multiple proteins acting upstream and downstream of the
mitochondria, determining the efficiency of apoptotic cell
death (Figure 1). Control over the integrity of mitochondrial
outer membrane is executed by the proteins of the B-cell
lymphoma 2 (Bcl-2) family, divided into three subfamilies: anti-
apoptotic (for example, Bcl-2, Bcl-Xl, Mcl-1, Bcl-w), pro-
apoptotic effectors (Bax and Bak) and BH3-only proteins (for
example, Bid, Puma, Bim, Bad and so on), which form a
complex network of interactions (discussed in more detail in
several reviews, including.6,37–39 Downstream of mitochon-
dria, activation of caspases is also heavily regulated, first by
the low-probability event of apoptosome formation and
second by inhibitor of apoptosis (IAP) proteins such as XIAP
(Figure 1).
In the extrinsic pathway of apoptosis, the initial stress signal
comes from the binding of a death domain-containing
receptor, located at the plasma membrane, to its cognate
ligand (for example, Fas ligand (FasL) or tumor necrosis
factor-a (TNF-a)).40 Upon binding, the receptor promotes the
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formation of the death-inducing complex (DISC) that activates
caspase-8 (Figure 1). In some cell types, caspase-8 cleaves
the BH3 protein Bid, forming truncated Bid (tBid) and
ultimately inducing the mitochondrial outer membrane per-
meabilisation. Thus, in some contexts, there is a cross talk
between the extrinsic and the intrinsic pathway of apoptosis.
Cardiomyocytes undergo apoptosis in response to a
plethora of stimuli including hypoxia (especially followed by
reoxygenation), acidosis, oxidative stress, glucose depriva-
tion and metabolic restriction, b1-adrenergic agonists, stretch,
angiotensin II (Ang II), TNF-a, Fas L and anthracyclines as
reviewed in.41 Even though it is often postulated that necrosis
is the main pathway responsible for cardiomyocyte death
following MI, several observations in human, rabbit, rat and
mice hearts indicate that apoptotic cell death contributes to
the overall cardiomyocyte loss followingMI, particularly during
subacute and chronic stages of infarction and after reperfu-
sion,42–47 as well as in end-stage cardiomyopathy and in
terminally failing human myocardium.48,49 Cardiomyocyte
apoptosis has also been shown to contribute to left ventricle
dysfunction following cardiac surgery,50 particularly after
retrograde cardioplegia.51 Moreover, inhibition of post-
ischemic cardiomyocyte apoptosis emerges as an effective
therapeutic avenue to improve diastolic heart function after
ischemia.52
Studies indicate the relevance of both themitochondrial and
the extrinsic pathway of apoptosis in cardiac pathologies. The
mitochondrial pathway of apoptosis is activated following
myocardial ischemia-reperfusion injury,53 whereas TNF-a, a
trigger of the death receptor pathway, is rapidly released from
resident mast cells and macrophages in response to
myocardial ischemia,54 and can also be released from
cardiomyocytes.55 Overexpression of FasL was also shown
to increase cardiomyocyte apoptosis in vitro and in vivo.56 The
fact thatmultiple cell death pathways are detectable and occur
side-by-side is not surprising, and is a common phenomenon
observed in contexts ranging from retrovirus-induced immu-
nosuppression57 to chemotherapy-induced cancer cell
death.58–60 Therefore, it is well recognized that activation of
a particular cell death pathway does not constitute sufficient
evidence to support its physiological importance in the
pathological process, and instead needs to be supported by
prevention of cell loss using pathway-specific pharmacologi-
cal and/or genetic inhibition. In this regard, conflicting results
have been published. For example, it was observed that Fas-
deficient Ipr mice exhibit reduced infarcts and diminished
apoptosis after myocardial ischemia-reperfusion (I/R) injury,
both ex vivo and in vivo,56,61 whereas in transgenic mouse
lines with cardiomyocyte-specific overexpression of Bcl-2 or
dominant-negative Fas-associated death domain (FADD)53
only inhibition of the mitochondrial pathway provided a
significant decrease in the size of infarction following coronary
artery ligation. Of note, in the latter study, there was still a
substantial decrease in the number of apoptotic (TUNEL
positive) cardiomyocytes in FADD dominant-negative mouse
line, suggesting that forms of cell death other than apoptosis
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Figure 1 A simplified schematic representation of the extrinsic and the intrinsic (mitochondrial) pathways of apoptosis and necroptosis. The mitochondrial (intrinsic)
pathway of cell death is regulated both upstream (Bcl-2 proteins) and downstream (e.g., IAP proteins) of mitochondria. In response to stress, mitochondria undergo
permeabilisation of the outer mitochondrial membrane (MOMP), which leads to a release of a number of pro-apoptotic factors such as cytochrome c, AIF or EndoG.
The extrinsic pathway of apoptosis is activated via a complex signal transduction from the plasma membrane, whereby the death receptors (e.g., Fas, TNFR) bind their
cognate ligands (e.g., FasL, TNF), oligomerize, activate their intracellular death domains and recruit a number of receptor-associated proteins such as RIP1 or TRADD.
The multiprotein complex then recruits the initiatior pro-caspase-8 leading to its activation. Active caspase-8 propagates the apoptotic signal either by direct activation
of executioner caspases, or by cleaving a BH3 protein Bid which then leads to MOMP. In addition, components of the protein machinery that regulates the extrinsic pathway of
apoptosis are also involved in regulation of necrosis. The figure also demonstrates apoptosis regulatory microRNA and their target genes in apoptotic pathways
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were contributing to the infarct size. In addition, in lpr mice
Fas-deficiency is not limited to cardiomyocytes. Therefore,
more studies in models where apoptosis contributes sig-
nificantly to the infarct, and where it is blocked specifically in
cardiomyocytes, are needed to provide more evidence as to
the role of specific apoptotic pathways.
MiRNAs that Regulate Cardiovascular Sensitivity to
Apoptosis
The role of miRNAs in regulating the expression of anti- and
pro-apoptotic genes and regulation of cardiomyocyte and
endothelial cell survival is well documented (Table 1). miRNAs
appear to regulate cardiomyocyte apoptosis through multiple
mechanisms. When it comes to the mitochondrial pathway of
apoptosis, several miRNAs target the BCL2 gene, including
miR-1, miR-15 family and miR-21, whereas PUMA and BIM,
which encode for the pro-apoptotic BH3 proteins, are targeted
by miR-149 and miR-214 (as well as miR-24), respectively
(Table 1). In addition, mitochondrial fission machinery is
regulated by miR-30 family, which targets the TP53 gene
encoding for p53 protein which in turn regulates the expres-
sion of mitochondrial fission protein dynamin-related protein-1
(Drp1), and by miR-761, which targets a gene encoding for
mitochondrial fission factor (Mff) (Table 1).62 Of note, a
particular recent study suggests that Mff is responsible for
recruiting Drp1 to the foci at the outer mitochondrial
membrane.63 Downstream of mitochondria, the expression
of CASP9, which encodes for the initiator caspase-9, is
regulated by miR-133a, whereas CASP3, which encodes for
the executioner caspase-3, is regulated bymiR-378 (Table 1).
In addition, miR-21 regulates genes involved in the death
receptor pathway of apoptosis, including death domain-
associated protein gene (DAXX) and FASLG, which encode
for death receptor-associated protein and Fas L, respectively
(Table 1).
Genes encoding proteins that control ROS signaling are
also enriched among the targets of apoptosis-regulating
cardiac miRNAs. In particular, three miRNAs, that is,
miR-34a, miR-195 andmiR-199a, target SIRT1 (Table 1), which
encodes for a foundingmember of a family of NAD-dependent
deacetylases called sirtuins. When expressed at low levels,
SIRT1 has been reported to protect cardiomyocytes from
oxidative stress and apoptosis, and stimulation of Sirt1 protein
mimics ischemic preconditioning and protects heart from I/R
injury (reviewed in greater detail by Sundaresan et al.64 and
Yamamoto and Sadoshima65). Other ROS signaling genes
targeted by cardiac miRNAs include TXN (encoding for
thioredoxin) and SOD (encoding for superoxide dismutase).
Interestingly, a study on mice with cardiac-specific over-
expression of Sirt1 revealed that it upregulates the expression
of both superoxide dismutase and thioredoxin 1.66 Consider-
ing that multiple miRNAs associated with apoptotic regulation
in cardiomyocytes impinge on the network of SIRT1-ROS
signaling, while some other miRNAs affect ROS-induced
signaling pathways, such as changes in free calcium (for
example, miR-14567), more research is required to delineate
the exact mechanism and causal role of miRNAs in maintain-
ing cardiac redox homeostasis as well as the cell death
regulatory role of redox-sensitive miRNAs.
Consistent with tissue-specific functions, many miRNAs
have distinct biological effects depending on the cell type. For
example, inhibition of miR-24 has been reported to promote
cardiomyocyte apoptosis while decreasing the survival of
endothelial cells.68 Considering this, more work is needed to
investigate the apoptosis-regulating effects of miR-17-92
cluster, which appears to be expressed at high level in the
heart and has been extensively reported to exert anti-
apoptotic effects in tumor cells.69 Only few studies, however,
have been reported so far with regards to the cardiac
apoptosis regulation by this miRNA cluster (see Table 1). Of
note, the variability in the role of miRNAs is observed not only
between the cell types, but also between cellular processes,
particularly as they relate to the effect on tissue functioning.
For example, in cardiacmyocytes, the signaling pathways that
regulate hypertrophy impinge also on the balance between
cell survival and cell death,70 and many miRNAs may be
involved in regulation of this delicate balance.
The striking abundance of miRNAs involved in the regula-
tion of apoptosis in cardiomyocytes suggests the possibility of
an extensive overlap of regulatory functions and effects on
intracellular signaling. Such synergy between miRNAs has
been recently investigated using receiver operating charac-
teristic (ROC) analysis, which indicated that miR-21 scores
high for its synergistic effects. Of particular interest, the
synergistic effect of miR-21 and miR-1 was detected, and
functionally validated in the context of regulation ofmyocardial
apoptosis, cardiac hypertrophy and fibrosis.71 Here, we have
used the integrated parameter synergy score calculations
(Figure 2), based upon the experimentally validated and
confidently predicted miRNA-target interaction data obtained
from miRSel72 and TargetscanHuman 6.2, to calculate the
synergy scores for the miRNAs linked to cardiomyocyte
apoptosis (Figure 3). In total, we identified 35 synergistic
(synergy score of more than 2.0) pair-wise combinations of
miRNAs. This finding confirms that the synergistic action of
these miRNAs on cardiomyocyte apoptosis should not be
ignored. As observed before,71 miR-21 was most commonly
involved in synergistic interactions (n¼ 10) (Figure 3a), with
particularly strong synergy between miR-21 and miR-1
(Figure 3b), followed by two miR-15 family members miR-
15a and miR-16 (each of them synergized with nine other
miRNAs). In comparison, several miRNAs were not involved
in synergistic interaction, as indicated by the synergy score
o2.0. These miRNAs include miR-133a, miR-149, miR-19b,
miR-210, miR-214, miR-30, miR-320, miR-378, miR-499 and
miR-761 (example given in Figure 3c). Overall, this analysis
indicates that there is a selective synergism among endo-
genous miRNAs in regulating complex biological processes
such as apoptosis.
In addition, we used the Ingenuity Pathway Analysis (IPA)
to determine network of connections between the identified
apoptosis-regulating miRNAs of reported relevance to cardi-
ovascular disease (Figure 4). We observed that many
miRNAs are regulated through each other either directly or
indirectly, and many are indirectly regulated by the same
signaling molecules, for example, beta estradiol (Figure 4). In
this context, it is interesting to note that to the best of our
knowledge, no experimental studies have been published so
far on estradiol-mediated regulation of cardiac miRNAs,
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Table 1 Summary of miRNAs linked to apoptotic regulation in cardiomyocytes
miRNAs Relevance to CVD Targets relevant to
apoptosis
Refs
miR-1 Serum expression upregulated in human AMI and in patients after open-heart surgery with
cardiopulmonary bypass
PRKCE
(protein kinase C)
147–159
Overexpression enhances and inhibition attenuates apoptosis and infarct area after cardiac I/R
injury in mice
HSPD1 (HSP60)
Overexpression inhibits apoptosis in a rat model of cardiac hypertrophy induced by pressure
overload
BCL2
Ischemic post-conditioning upregulates miR-1 and inhibits cardiomyocyte apoptosis in rats
Inhibition in vitro in cardiomyocytes reduces H2O2-induced and high-glucose-induced
apoptosis
Upregulation has pro-apoptotic effect in H9c2 cells exposed to oxidative stress
miR-1 transfected ES cells protect host myocardium from MI-induced apoptosis
overexpression enhances the angiogenic differentiation of human cardiomyocyte PC
Upregulated in rat cardiomyocytes exposed to high glucose
Downregulated in response to Tanshinone IIA
miR-15
family
Upregulated in response to MI
Silencing in vitro renders cardiomyocytes resistant to hypoxia-induced cell death
BCL2 160–163
Regulates angiogenic activity of endothelial cells
miR-133a Upregulation of miR-133a following ischemic post-conditioning CASP9 155,156,164,165
miR-133a mimic attenuated IR-induced apoptosis in rats
Anti-apoptotic effect in H9c2 cells exposed to oxidative stress
Elevated levels of miR-133a in patients with ST-elevation myocardial infarction (STEMI) linked
to more severe injury
Increased expression in Tanshinone IIA-treated hypoxic neonatal cardiomyocytes
miR-17-92
cluster
Overexpression of the cluster results in lethal cardiomyopathy
Expression decreases in aging mice hearts
166–169
miR-20a is upregulated in mechanically stretched neonatal rat cardiomyocytes and exerts anti-
apoptotic effect
Overexpression of miR-19b inhibits apoptosis in P19 cells
miR-21 Myocardial upregulation of miR-21 reducesMI size and apoptotic rate by increasing Bcl-2 levels BCL2 FASLG (FASL) 170–176
Expression declines in cardiac myocytes upon exposure to hypoxia, and increases after
ischemic preconditioning
PDCD4
Overexpression diminishes murine coxsackievirus B3-induced myocardiatis ANXA2
Overexpression in transgenic mouse heart results in smaller infarct following ischemia SOD2 TXNDAXX
Expression elevated in circulating endothelial progenitor cells from diabetic patients and
protective from high-glucose-induced apoptosis
Expressed in cardiac valve endothelium, where it regulates the development of AV valve
miR-24 Expression lower in peri-infarct tissue in mouse model of MI BIM 68,177
Inhibition induces cardiomyocyte apoptosis
In vivo overexpression inhibits cardiomyocyte apoptosis and attenuates infarct size
Inhibition enhances EC survival
miR-30 Inhibits mitochondrial fission and apoptosis in cardiomyocytes TP53 178
miR-150 Upregulated in cardiac myocytes treated with H2O2 MYB (c-myb) 147,179
Silencing protects from H2O2-induced apoptosis
Dysregulated in human MI
miR-210 Upregulated in hypoxic cardiomyocytes ? 147,180
Overexpression reduces cell death in response to oxidative stress
Deregulated in human MI
miR-199a Downregulated to undetectable levels during cardiac ischemia in vitro and in vivo HIF1A SIRT1 181
Overexpression inhibits hypoxia-induced expression of several pro-apoptotic genes (e.g.
CASP3 and CASP9)
miR-320 Downregulated in murine hearts following I/R HSPB6 (Hsp20) 182
Overexpression enhanced cardiomyocyte apoptosis
miR-149 Overexpression decreases apoptotic sensitivity BBC3 (PUMA) 183
G-allele of A4G SNP in pre-miR-149 decreases production of miR-149 and influences cardiac
function in mouse model of MI
miR-761 Inhibits mitochondrial fission MFF 62
Knockdown diminished H2O2-induced and I/R-induced cardiomyocyte apoptosis and infarct
size in mice
miR-499 Inhibits cardiomyocyte apoptosis PPP3CA, PPP3CB 184
miR-214 Protects cardiomyocytes from H2O2-induced apoptosis in vitro PTEN BIM 185,186
Genetic deletion in mice increases cardiac apoptosis
miR-145 Circulating levels reduced in patients with coronary artery disease CAMK2G 67,187
Ameliorates ROS-induced apoptosis in cardiomyocytes
miR-378 Downregulated in a rat model of myocardial ischemia CASP3 188
Overexpression in H9c2 cardiomyocytes reduces apoptosis and necrosis
Inhibition increases H2O2-induced apoptosis
miR-195 Inhibition leads to decreased ROS production and apoptosis in palmitate-treated mouse
cardiomyocytes
SIRT1 189
miR-34a Expression increases with aging (in mice) SIRT1 PNUTS 125,190,191
Inhibition reduces cardiomyocyte apoptosis
Levels higher in endothelial progenitor cells from coronary artery disease patients
Regulates SIRT1 expression in endothelial progenitor cells and contributes to endothelial
senescence
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despite awell-recognized cardioprotective (via an anti-apoptotic
mechanism) function of estrogen.73–86
Autophagy, a Double-Edged Sword in Cardiovascular
Disease
Autophagy is an evolutionarily conserved mechanism of
cellular self-digestion in which long-lived proteins and entire
organelles are degraded through delivery to lysosomes
(Figure 5). It is characterized by the formation of autophago-
somes, cellular structures that encapsulate cytoplasmic
cargoes. Autophagosomes ultimately fuse with lysosomes to
form autolysosomes in which the contents are degraded into
their constituent parts and delivered back into the cytosol for
further biocatalysis or to be utilized in biosynthetic pathways.
It is well documented that basal levels of autophagy,
operating in the majority, if not all, cells, serve to maintain
homeostasis by removing misfolded or aggregated proteins,
and by clearance of damaged organelles such as mitochon-
dria and endoplasmic reticulum.87,88 Both the rate of
autophagy and the selection of cargoes destined for degrada-
tion can, however, change in response to specific external and
internal cues. In this context, excessive autophagy, induced in
response to stress signals, can have dual effects, acting either
to maintain cell survival (for example, by providing essential
energy for sustaining physiological function during the times of
catabolic defects) or contributing to cell death (e.g., by
diminishing cell volume or providing energy for the execution
of apoptosis).
Defects in the process of autophagy have been implicated
in numerous human diseases, including cardiovascular
diseases such as hypertrophy and heart failure (reviewed in
Marzetti et al.89–92). Moreover, induction of autophagy by
perioperative ischemia/reperfusion has been observed.93
Considering that autophagy can potentially exert both pro-
and anti-survival function, it is not surprising that its role in
cardiovascular disease remains relatively poorly understood,
with some studies pointing toward its beneficial effects,94–99
while others suggest its detrimental role.100 Nevertheless, the
preponderance of evidence supports the notion of beneficial
role for autophagy in the heart.
MiRNAs and Cardiovascular Autophagy: The Causality
Dilemma
The role of miRNAs in regulation of autophagy was first
suggested in 2009, when BECN1, a gene encoding for Beclin
1 which is an important factor controlling vesicle nucleation
(see Figure 5), was shown to be posttranscriptionally
regulated by miR-30a.101 Since then, multiple miRNAs have
been linked to the autophagic pathway and have been
associated with disease states, including cardiac pathologies
(Table 2). In addition, there are several miRNAs that have
been reported to modulate autophagy in other tissues, and
have also known roles in cardiac function. For example, in
hematopoietic cells, miR-17 has been shown to regulate the
expression of SQSTM1 (p62), an ubiquitin-binding protein and
regulator of autophagy-mediated protein degradation,102 and
the expression of ATG7 in glioblastoma cells.103 It also
appears to modulate cardiac remodeling following MI.104
Whether miR-17 regulates cardiac autophagy remains to be
investigated.
We conducted pathway analysis of miRNAs linked to cardiac
autophagy, using the Ingenuity Pathway Analysis (IPA)
software (Ingenuity Systems, Qiagen, Redwood City, CA,
USA), and discovered two main nodes of interaction, that is
p53 and STAT3 (signal transducer and activator of transcription
3) (Figure 6). Interestingly, both p53 and STAT3 are known as
critical regulators of autophagy. Specifically, STAT3 inhibitors or
genetic ablation stimulate autophagic flux,105,106 and reduced
levels of STAT3 are reported in patients with end-stage heart
failure.107,108 Moreover, the activation of STAT3 by angiotensin
(Ang)II-induced Janus-activated kinase 2 (JAK-2) is impaired in
failing human cardiomyocytes.109 With regards to p53, its
inhibition is cardioprotective against ischemic injury, and an
increase in autophagic flux has been observed in p53 ( / )
heart under ischemic conditions.110 This effect is suggested to
occur through the p53-TIGAR axis,110 with TIGAR (TP53-
induced glycolysis and apoptosis regulator) being involved in
regulation of the glycolysis and pentose phosphate pathway,
ROS-levels, and inhibition of apoptosis and autophagy.111,112
The p53-TIGAR axis has also been specifically shown to
regulate cellular energy homeostasis and cell death in
cardiomyocytes under ischemic stress.113 There is a need for
more detailed studies on the role of miRNAs in regulation of
such complex signaling pathways, and their role in the context of
myocardial cell death.
At the Crossroad of Apoptosis and Autophagy
It is a hackneyed expression that simultaneous induction of
multiple cell signaling pathways occurs in biological systems,
but it is nonetheless true, even in the context of concurrent
induction of cell death and cell survival pathways. Concomitant
Synergistic
Non-synergistic Non-synergistic
Synergistic
Figure 2 A graphic representation for quantitative assessment of miRNA
synergy. (a) Targeting more common genes creates synergy between two miRNAs.
(b) Denser functional association between proteins encoded by individual miRNA-
target genes makes two miRNAs more likely to act synergistically
MicroRNAs in cardiomyocyte death
J Skommer et al
6
Cell Death and Disease
Figure 3. miRNA synergy in cardiac apoptosis. (a) Synergy score calculation for random combinations of validated miRNAs that are involved in cardiac apoptosis.
Synergy scores of more than 2.0 are highlighted as thick red-dash lines. (b) Network location of apoptosis-related proteins encoded by target genes of miR-1 (red nodes),
miR-21 (green nodes) and both (yellow nodes). (c) Network location of apoptosis-related proteins encoded by target genes of miR-1 (red nodes), miR-30 (blue nodes) and
both (purple nodes). Synergistic apoptosis regulation should be expected for the pair of miR-1 and miR-21 instead of miR-1 and miR-30, due to more common target genes
and denser functional association between gene-encoded products. Synergy scoremiR-1:miR-21¼ 3.23; Synergy scoremiR-1:miR-30¼ 1.13; Box shows the network core area
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induction of autophagic and apoptotic signaling, and the
extensive cross talk between these two pathways have been
reported extensively in cancer cells114 and also in cardiac
cells.115 In general, the nodes of cross talk includeBeclin-1–Bcl-2
interaction (reviewed in Marquez and Xu116), Beclin-1–Bim
interaction,117,118 caspase-mediated Beclin 1 cleavage,119,120
caspase- and calpain-mediatedAtg5 cleavage,121UVRAG–BAX
interaction,122 ATG12–Mcl-1 and ATG12–Bcl-2 interaction,123
ATG5–FADD interaction,124 p53-mediated cross regulation,111
as well as regulation of Akt signaling that has differential effects
on autophagy and apoptosis (Figure 7).
Several models can be put forward to suggest the possible
role of miRNAs in regulation of autophagic–apoptotic cross
talk. Firstly, different transcripts can share a common miRNA-
binding site and compete for the same miRNA. It can be
envisaged that overexpression of one of the transcripts, for
example, one that regulates apoptosis, could leave less
miRNAs free to bind the autophagy-related transcript (a
buffering effect) and thus shift the balance between apoptosis
and autophagy. Secondly, any miRNA regulating the expres-
sion of genes that encode the autophagy–apoptosis node
proteins listed above can contribute to the switch between the
two pathways. Finally, miRNAs that target histone deacety-
lases (such as sirtuins), which regulate the expression of both
autophagic and apoptotic genes, are likely to impact the
dynamic relationship between these two pathways.
As yet, the role of miRNAs that potentially affect the cross
talk between apoptosis and autophagy on cardiac cell survival
and tissue homeostasis remains largely unknown. Recent
studies identified that genetic deletion of aging-associated
miR-34a reduces cardiomyocyte cell death and improves
functional recovery after MI, which is attributed to the function
of a novel miR-34a target gene,PNUTS.125 One of the cellular
effects of Pnuts protein is nuclear sequestration of Pten,126 a
negative regulator of Akt, which in turn is a master regulator of
both apoptosis and autophagy (Figure 7). Moreover, another
miR-34a target, SIRT1, is known to regulate both apoptosis
(via a p53 pathway and ROS signaling) and autophagy
Figure 4 Ingenuity Pathway Analysis of the miRNAs identified as involved in regulation of cardiomyocyte apoptosis (see Table 1). The analysis revealed several regulatory
nodes, with one particularly interesting being the oestradiol regulation (highlighted in red) of several of the miRNAs
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(via p53 and the activation of FoxO transcription factor family
members).127,128 Thus, miR-34a-mediated regulation of
PNUTS and SIRT1 expression in cardiac cells could contribute
to changes in apoptosis–autophagy switch in response to
stress and during cardiac recovery and remodeling.
Interestingly, increased levels of the miRNA miR-34a
appear to be also associated with telomere shortening, with
overexpression of PNUTS in human cardiomyocytes leading
to telomere attrition.125 Telomere shortening is a well-known
trigger of cellular senescence and has also been associated
with several CVDs, including MI and the onset and progres-
sion of arterial hypertension.129 Contrary to cell death,
senescence is a process of irreversible cell cycle arrest which
allows cells to remain viable andmetabolically active for a long
time (at least in in vitro cell culture). Cells undergoing
senescence exhibit several phenotypic changes, including
enhanced autophagy, the role of which, according to a recent
study, is to process cytoplasmic chromatin fragments budded
off nuclei.130 Another miR-34a target gene, SIRT1, is also
known to influence certain aspects of vascular ageing,
including senescence.131,132 This suggests another mechan-
ism for miRNA-regulated cardiomyocyte autophagy involving
senescence signaling pathways.
miRNAs in Cardiovascular Necrosis
Necrosis is a type of cell death which is morphologically
characterized by increase of cell volume, dilation of orga-
nelles, rupture of the plasma membrane and subsequent loss
of intracellular contents.34 For a long time, necrosis was
considered to be a passive, accidental and unregulated form
of cell death, and as such was sharply contrasted against
heavily regulated and tightly orchestrated apoptosis. This
view has changed over the last few years, with increasing
number of reports describing the regulatory network that
governs necrotic cell death (reviewed in Henriquez et al.133
and Wu et al.134). Many authors suggest that myocardial
ischemia results predominantly in necrotic cell death,135 due
to depletion of ATP, increased calcium load, acidosis and
severe oxidative stress, with apoptotic cell death playing a role
following reperfusion. Accordingly, inhibitors of necrotic cell
death appear to be effective at reducing myocardial cell death
and infarct size in animal models.136 In addition, myocardial
necrosis is relatively common among infants who die as a
result of congenital heart disease, perinatal asphyxia, sepsis
or coronary artery abnormalities.137
So far, only limited evidence has been gathered on the role
of miRNAs in regulation of cardiac necrosis. A recent study
has reported that miR-874 inhibits cardiomyocyte necrosis,
in vitro as well as in animal model of MI, via downregulation of
Atg12-Atg5-Atg16L
Beclin1
LC3-I
Isolation
membrane
cytosol
EXPANSION
INDUCTION
LC3-II
COMPLETION
autophagosome
Bafilomycin A
FUSION
BREAKDOWN
EFFLUX
(cargoselection) 
NUCLEATION
amino-acids
fatty-acids
Biosynthesis
(ATP)
cargo material
Figure 5 Key steps in the autophagic pathway. The process is initiated by the
formation of autophagosomes, double-membrane vesicles that engulf fractions of
the cytosol. Autophagosomes undergo a step-wise maturation associated with
expansion and completion of the sequestering vesicle, which is regulated by many
ATG proteins, particularly Beclin-1 and two ubiquitin-like conjugation systems
Atg12-Atg5-Atg16L and Atg8(LC3)-PE. Autophagosomes then fuse with lysosomes
to form single-membrane autolysosomes. In this process, autophagosomes acquire
hydrolytic enzymes and are able to degrade the sequestered material. Recycling of
the basic components, such as amino or fatty acids, helps the cell to maintain
homeostasis
Table 2 Autophagy-modulating miRNAs with relevance to CVD
miRNAs Relevance to CVD Targets relevant to
autophagy
Function Refs
miR-30 Downregulated in a model of cardiac hypertrophy and by
angiotensin II
BECN1 Vesicle nucleation 192
Circulating miR-30 elevated in patients with left-ventricular
hypertrophy
miR-204 Reduces cardiomyocytes autophagy in response to hypoxia-
reoxygenation
193,194
Concomitant downregulation of miR-204 and induction of
autophagy following cardiac ischemia-reperfusion in rats
MAP1LC3A Vesicle maturation and
fusion with the lysosome
195
Downregulated in pulmonary arterial smooth muscle cells from
patients with PAH
miRNA-212/132 Impaired autophagy in starved cardiomyocytes FOXO3 PTEN Pro-autophagic transcrip-
tion factor
196
Induced cardiac hypertrophy
miR-21 Cell treatment with anti-miR-21 induced autophagy BECN1 MAP1LC3A
PIK3C3 (VPS34)
197
Not yet investigated with regards to cardiomyocte autophagy
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the expression of caspase-8,138 which normally serves not
only as an element of the death receptor pathway, but also as
a pro-survival regulator that supresses necrosis.139 Apart
from caspase-8, other components of death receptor path-
way, for example, receptor interacting protein 1 (RIP1), are
also involved in regulation of necrosis (see Figure 1). In this
regard, overexpression of miR-155 was reported to attenuate
necrotic cell death in cardiomyocyte progenitor cells exposed
to hydrogen peroxide.140 Considering the continuum and
interdependence of cell death pathways, as well as the clinical
importance of necrosis in conditions such as myocardial
infarction, more work is needed to decipher the exact role of
miRNAs in necrotic cell death.
Necroptosis is a specialized pathway of programmed
necrosis (Figure 1), targeting the kinase RIP1 involved in
extrinsic pathway of apoptosis.141 Necroptosis shares char-
acteristics of both necrosis and apoptosis.142,143 A study on
mice model has showing that a bolus dose of necroptosis
inhibitor, necrostatin-1, in mice at the time of coronary
reperfusion dramatically reduced infarct size after I/R njury.144
These results indicates important role of necroptosis in
regulation of cardiac cell death. Involvement of necroptosis
in myocardia injury after Mi and in other cardiovascular
conditions has not been investigated in detail. Further
investigation on this pathway may hold promise for finding
further clinical targets for treating heart diseases.
Can miRNAs Regulate Cell-to-Cell Variability in Cardiac
Cell Death?
The performance of the apoptotic network determines the
individual cell’s probability to die, which, when assessed over
a large population of cells, can be translated into the percent of
cell death at a given time point. The apoptotic pathway
consists of many processes that are stochastic in nature, that
is, occur with certain probability rather than in a deterministic
fashion. These processes include protein translocation (e.g.,
translocation of Bax from the cytosol to mitochondria) or
formation of multiprotein complexes (e.g., the apoptosome).
The architecture of the network includes also positive and
negative feedback loops, which may buffer or enhance the
inherent noise in the apoptotic signaling. Therefore, the net
balance between the amount of pro- and anti-apoptotic
proteins, the spatial and temporal availability of protein
partners for interaction and functioning of the feedback loops
are all critical for determining the performance of the apoptotic
network and thus the threshold of stress signal required for
successful execution of cell death at the level of cell
population.
Gene expression is subject to stochastic variability even
among the cells with the same genotype and environment.145
The inherent stochastic nature of transcriptional regulation
affects cell ability to control gene expression levels in
response to extracellular stimuli, including stress cues. In
the context of cell death, such cell-to-cell variability translates
to dramatic differences in the time between exposure to stress
and the execution of cell demise.9,12 The differences in
kinetics of cell death are particularly pronounced when critical
events involve small numbers of molecules, for example,
apoptosome formation. Importantly, for many genes, the
noise in the expression pattern increases as their expression
decreases. As miRNAs affect cell homeostasis by regulating
gene expression, it is conceivable that they inherently
contribute to the cell-to-cell variability in cell signaling as well
as to the robustness of cell phenotypes and responses to
stimuli, including pro-apoptotic stimuli. This field of research
remains, as of now, largely unexplored, with only a few
attempts to analyze the stochastic properties of regulatory
clusters involving miRNAs.146 It is, nevertheless, and exciting
avenue with potentially far-reaching implications when it
comes to regulation of cardiomyocyte cell death, particularly
in the contexts of a delayed and slow-progressing response
outcome of which can be substantially affected by changes in
cell-to-cell variability. This line of research will require not only
knowledge of the effects of specific miRNAs on oscillations in
gene expression patters but also stochastic version of
deterministic models employed traditionally to study cell
signaling pathways.
Figure 6 Ingenuity network analysis of miRNAs identified as regulators of
autophagy in cardiomyocytes (and miR-21)
PTEN
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PIP3 PIP2
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Figure 7 MiR-34a as potential regulator of the cross talk between autophagic
and apoptotic signaling in cardiac cells. PNUTS is a PTEN-associated protein that
sequesters PTEN to the nucleus127
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Summary and Future Outlook
Through an in-depth analysis of the current evidence linking
miRNAs with regulation of cardiomyocyte cell death path-
ways, and the understanding of regulatory nodes (including
cross talks between the pathways and non-genetic regulation
of cell-to-cell variability in cell death), we have identified
several new research avenues, pursuit of which may be of
pivotal importance to our understanding of regulatory circuits
that govern survival and death of cardiomyocytes. These
avenues include the role of redox-sensitive miRNAs, the
effects of beta estradiol in regulation of miRNAs expression
and action in the heart, the role of miRNAs in regulating the
balance between pro-survival and death pathways as well as
cell-to-cell variability in timing and extent of phenotypic
response. The emerging systems-biology approach to study-
ing the functional synergy between cardiac miRNAs in the
context of cell death pathways should be extended to
incorporate more extended network of signaling pathways,
including ROS signaling. This should help to elucidate the full
impact of miRNAs on gene expression networks and
biological pathways. In the context of these observations,
there is a need for investigation of aging-associated cardiac
miRNAs that affect cell death pathways. Further studies are
also required to understand mechanisms responsible for
reported cardiac microRNA changes during myocardial
infarction, chronic kidney disease, hypertension, diabetes
and other cardiac pathological conditions of cardiac death.
Analysis of the fine balance between the apoptotic and
hypertrophic roles of cardiac miRNAs will contribute to the
understanding of the complex interactions between multiple
cardiac-specific miRNAs in aging. We envisage that all these
studies will form a solid framework for development of future
therapies for the treatment of cardiovascular diseases, based
on anti-miR/miRNA overexpression approaches.
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